Whole-exome sequencing confirmation of a novel heterozygous mutation in RUNX1 in a pregnant woman with platelet disorder

References

• Levy JA, Murphy LD. Thrombocytopenia in pregnancy. J Am Board Fam Pract 2002;15:290–297
   PubMedGoogle Scholar
• Silver R, Berkowitz R, Bussel J. Thrombocytopenia in pregnancy: ACOG Practice bulletin 1999;6:1–12
   Google Scholar
• Burrows RF, Kelton JG. Thrombocytopenia at delivery: A prospective survey of 6715 deliveries. Am J Obstet Gynecol 1999;162:731–734
   Google Scholar
• Ajzenberg N, Dreyfus M, Kaplan C, Yvart J, Weill B, Tchernia G. Pregnancy-associated thrombocytopenia revisited: Assessment and follow-up of 50 cases. Blood 1998;92:4573–4580
   PubMedGoogle Scholar
• Savoia A, Balduini CL. MYH9-related disorders. GeneReviews http://www.ncbi.nlm.nih.gov/books/NBK2689/
   Google Scholar
• Balduini CL, Savoia A. Genetics of familial forms of thrombocytopenia. Hum Genet 2012;131:1821–1832
   PubMed Web of Science ®Google Scholar
• Guéguen P, Rouault K, Chen JM, Raguénès O, Fichou Y, Hardy E, Gobin E, Pan-Petesch B, Kerbiriou M, Trouvé P, et al. A missense mutation in the alpha-actinin 1 Gene (ACTN1) is the cause of autosomal dominant macrothrombocytopenia in a Large French Family. PLoS One 2013;17:e74728
   Google Scholar
• Nurden P, Dedili N, Coupry I, Bryckaert M, Youlyouz-Marfak I, Solé G, Pons AC, Berrou E, Adam F, Kauskot A, et al. Thrombocytopenia resulting from mutation in filamin A can be expressed as an isolated syndrome. Blood 2011;118:5928–5937
   PubMed Web of Science ®Google Scholar
• Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, Favier R, Bernstein A. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000;13:176–177
   Google Scholar
• Kunishima S, Kobayashi R, Itoh TJ, Hamaguchi M, Saito H. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009;113:458–461
   PubMed Web of Science ®Google Scholar
• Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999;23:166–175
   PubMed Web of Science ®Google Scholar
• Kunishima S, Kashiwagi H, Otsu M, Otsu M, Takayama N, Eto K, Onodera M, Miyajima Y, Takamatsu Y, Suzumiya J, et al. Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 2011;117:5489–5484
   Google Scholar
• Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombocytopenia: A review of ITGA2B and ITGB3 defect with emphasis on variants, phenotypic variability, and mouse models. Blood 2011;118:6673–6680
   Google Scholar
• Noris P, Perrota S, Seri M, Pecci A, Gnan C, Loffredo G, Pujol-Moix N, Zecca M, Scognamiglio F, De Rocco D, et al. Mutations in ANKRD26 are responsible for a frequent from of inherited thrombocytopenia: Analysis of 78 patients from 21 families. Blood 2011;117:6673–6680
   PubMed Web of Science ®Google Scholar
• Morison IM, Cramer Bordé EM, Cheesman EJ, Cheong PL, Holyoake AJ, Fichelson S, Weeks RJ, Lo A, Davies SM, Wilbanks SM, et al. A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia. Nat Genet 2008;40:387–389
   PubMed Web of Science ®Google Scholar
• Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, Zivony-Elboum Y, Gumruk F, Cetin M, Khayat M, Boerkel CF, Kfir N, Huang Y, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet 2011;43:732–734
   PubMed Web of Science ®Google Scholar
• Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754–1760
   PubMed Web of Science ®Google Scholar
• Cerritelli SM, Crouch RJ. Ribonuclease H: The enzymes in eukaryotes. FEBS J 2009;276:1494–1505
   PubMed Web of Science ®Google Scholar
• McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altschuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: A MapReduce framework for analyzing next-generation NDA sequencing date. Genome Res 2010;20:1297–1303
   PubMed Web of Science ®Google Scholar
• DePristo MA, Branks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing date. Nat Genet 2011;43:491–498
   PubMed Web of Science ®Google Scholar
• Wang K, Li M, Hakonarson H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing date. Nucleic Acids Res 2010;38:e164
   PubMed Web of Science ®Google Scholar
• Buijs A, Poddighe P, van Wijk R, van Solinge W, Borst E, Verdonck L, Hagenbeek A, Pearson P, Lokhorst H. A novel CBFA2 single nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. Blood 2001;98:2856–2858
   PubMed Web of Science ®Google Scholar
• Jongmans MC, Kuiper RP, Carmichael CL, Wilkins EJ, Dors N, Carmagnac A, Schouten-van Meetern AY, Li X, Stankovic M, Kamping E, et al. Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: Clues for improved identification of the FPD/AML syndrome. Leukemia 2010;24:242–246
   PubMed Web of Science ®Google Scholar
• Agarwal N, Willmott FJ, Bowles L, Pasi KJ, Beski S. Case report of grey platelet syndrome in pregnancy. Haemophilia 2011;17:815–829
   PubMedGoogle Scholar
• Balduini CL, Pecci A, Noris P. Inherited thrombocytopenia’s: The evolving spectrum. Hämostaseologie 2012;32:259–270
   PubMed Web of Science ®Google Scholar
• Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, et al. In vitro analysis of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: Implications for mechanisms of pathogenesis. Blood 2002;99:1364–1372
   PubMed Web of Science ®Google Scholar
• Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M, Newman M, Roudaia L, Speck CL, Gu TL, et al. Disease mutation in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. Embo J 2007;26:1163–1175
   PubMed Web of Science ®Google Scholar
• Zhang DE, Fujioka K, Hetherington CJ, Shapiro LH, Chen HM, Look AT, Tenen DG. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol 1994;14:8085–8095
   PubMed Web of Science ®Google Scholar
• Sun W, Graves BJ, Speck NA. Transactivation of the Moloney murine leukemia virus and T-cell receptor β-chain enhancer by cbf and ets requires intact binding sites for both protein. J Virol 1995;69:4941–4949
   PubMed Web of Science ®Google Scholar
• Cockelill PN, Osborne CS, Bert AG, Grotto RJ. Regulation of GM-CSF gene transcription by core-binding factor. Cell Growth Differ 1996;7:917–922
   PubMedGoogle Scholar
• Austin GE, Zhao WG, Regmi A, Lu JP, Braun J. Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene. Leuk Res 1998;22:1037–1048
   PubMedGoogle Scholar
• Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBF β proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol 1994;14:5558–5563
   PubMed Web of Science ®Google Scholar
• Michaud J, Simpson KM, Escher R, Buchet-Poyau K, Beissbarth T, Carmichael C, Ritchie ME, Schütz F, Cannon P, Liu M, et al. Integrative analysis of RUNX1 downstream pathway and target genes. BMC Genomics 2008;31:363
   Google Scholar
• Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N, Dhedin N, André JM, Cornillet-Lefebvre P, Baruchel A, et al. High frequency of RUNX1 bialleic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 2009;113:5583–5587
   PubMed Web of Science ®Google Scholar
• Liew E, Owen C. Familial myelodysplastic syndromes: A review of the literature. Haematologica 2011;96:1536–1542
   PubMed Web of Science ®Google Scholar
• Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: Prognostic implication and interaction with other gene alterations. Blood 2009;114:5352–5361
   PubMed Web of Science ®Google Scholar
• Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, Jackson SC, Poon MC, Sinclair GD, Leber B, et al. Five new pedigrees with inherited RUNX1 mutation causing platelet disorder with propensity to myeloid malignancy. Blood 2008;112:4639–4645
   PubMed Web of Science ®Google Scholar
• Heller PG, Glembotsky AC, Gandhi MJ, Cummings CL, Pirola CJ, Marta RF, Kornblihtt LI, Drachman JG, Molinas FC. Low Mpl receptor expression in a pedigree with familial platelet disorder with predisposition to acute myelogenous leukemia and a novel AML1 mutation. Blood 2005;105(12):4664–4670
   PubMedGoogle Scholar
• Jalagadugula G, Mao G, Kaur G, Goldfinger LE, Dhanasekaran DN, Rao AK. Regulation of platelet myosin light chain (MYL9) by RUNX1: Implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood 2010;116:6037–6045
   PubMed Web of Science ®Google Scholar
• Sun L, Mao G, Rao AK. Association of CBFA2 mutation with decreased platelet PKC-theta and impaired receptor-mediated activation of GPIIb-IIIa and pleckstrin phosphorylation: Proteins regulated by CBFA2 play a role in GPIIb-IIIa activation. Blood 2004;103:948–954
   PubMed Web of Science ®Google Scholar
• Aneja K, Jalagadugula GS, Mao G, Rao AK. Mechanism of platelet factor (PF4) deficiency with RUNX1 mutations: RUNX1 is a transcriptional regulator of PF4. ASH Ann Meet Abstr 2009;114:227
   Google Scholar
• Dowton SB, Beardsley D, Jamison D, Blattner S, Li FP. Studies of a familial platelet disorder. Blood 1985;65:557–563
   PubMed Web of Science ®Google Scholar
• Ho CY, Otterud B, Legare RD, Varvil T, Saxena R, DeHart DB, Kohler SE, Aster JC, Dowton SB, Li FP, et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. Blood 1996;87:5218–5224
   PubMed Web of Science ®Google Scholar
• Kirito K, Sakoe K, Shinoada D, Takiyama Y, Kaushansky K, Komatsu N. A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. Haematologica 2008;93:155–156
   PubMed Web of Science ®Google Scholar